A randomised open label study to evaluate the safety and efficacy of imiquimod 5% cream applied 3 times per week for 8 or 12 weeks in the treatment of low risk nodular basal cell carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2011
At a glance
- Drugs Imiquimod (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 31 Oct 2007 Final results have been published (1087409)
- 23 Oct 2005 New trial record.